BRCA Carriers Have Improved Survival in Ovarian Cancer
For patients with invasive epithelial ovarian cancer (EOC), BRCA1 and BRCA2 mutations are associated with improved five-year survival, according to a study.
For patients with invasive epithelial ovarian cancer (EOC), BRCA1 and BRCA2 mutations are associated with improved five-year survival, according to a study.
Parents are more likely than not to tell their sons and daughters younger than 25 years whether or not the parent carries inheritable mutations in BRCA1 or BRCA2 genes.
Women with a variant of the KRAS oncogene are three times more resistant to platinum chemotherapy, the standard treatment for ovarian cancer, than are women without this variant.
A poly(ADP-ribose) polymerase (PARP) inhibitor that has shown promising anticancer activity in the presence of BRCA1 or BRCA2 gene mutations also appears to be effective in the treatment of more common, nonhereditary ovarian tumors.